Abstract
Modafinil (MOD) it has to be considered as a wake-inducing drug to treat sleep disorders such as excessive sleepiness in narcolepsy, shift-work disorder, and obstructive/sleep apnea syndrome. Current evidence suggests that MOD induces waking involving the dopamine D1 receptor. However, little is known regarding the molecular elements linked in the wake-promoting actions of MOD. Since the D1 receptor activates the mitogen-activated protein kinase (MAP-K) cascade, it raises the interesting possibility that effects of MOD would depend upon the activation of MAP-K. Here we tested the expression of MAP-K in hypothalamus as well as pons after the microinjection of MOD (10 or 20μg/1μL) in rats into anterior hypothalamus, a wake-inducing brain area. Intrahypothalamic injections of MOD promoted MAP-K phosphorylation in hypothalamus and pons. Taken together, these results suggest that the wake-inducing compound MOD promotes the MAP-K phosphorylation.
Keywords: Dopamine, hypothalamus, modafinil, narcolepsy, protein, pons, rat, wakefulness, western blot.
CNS & Neurological Disorders - Drug Targets
Title:Intrahypothalamic Administration of Modafinil Increases Expression of MAP-Kinase in Hypothalamus and Pons in Rats
Volume: 14 Issue: 4
Author(s): Alwin Poot-Ake, Stephanie Mijangos-Moreno, Danielle Manjarrez-Martin, Ramses Jimenez-Moreno, Pedro R. Aquino-Hernandez, Elda Pacheco-Pantoja, Oscar Arias-Carrion, Andrea Sarro-Ramirez, Gloria Arankowsky-Sandoval and Eric Murillo-Rodriguez
Affiliation:
Keywords: Dopamine, hypothalamus, modafinil, narcolepsy, protein, pons, rat, wakefulness, western blot.
Abstract: Modafinil (MOD) it has to be considered as a wake-inducing drug to treat sleep disorders such as excessive sleepiness in narcolepsy, shift-work disorder, and obstructive/sleep apnea syndrome. Current evidence suggests that MOD induces waking involving the dopamine D1 receptor. However, little is known regarding the molecular elements linked in the wake-promoting actions of MOD. Since the D1 receptor activates the mitogen-activated protein kinase (MAP-K) cascade, it raises the interesting possibility that effects of MOD would depend upon the activation of MAP-K. Here we tested the expression of MAP-K in hypothalamus as well as pons after the microinjection of MOD (10 or 20μg/1μL) in rats into anterior hypothalamus, a wake-inducing brain area. Intrahypothalamic injections of MOD promoted MAP-K phosphorylation in hypothalamus and pons. Taken together, these results suggest that the wake-inducing compound MOD promotes the MAP-K phosphorylation.
Export Options
About this article
Cite this article as:
Poot-Ake Alwin, Mijangos-Moreno Stephanie, Manjarrez-Martin Danielle, Jimenez-Moreno Ramses, Aquino-Hernandez R. Pedro, Pacheco-Pantoja Elda, Arias-Carrion Oscar, Sarro-Ramirez Andrea, Arankowsky-Sandoval Gloria and Murillo-Rodriguez Eric, Intrahypothalamic Administration of Modafinil Increases Expression of MAP-Kinase in Hypothalamus and Pons in Rats, CNS & Neurological Disorders - Drug Targets 2015; 14 (4) . https://dx.doi.org/10.2174/1871527314666150429113609
DOI https://dx.doi.org/10.2174/1871527314666150429113609 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emerging Role of JNK in Insulin Resistance
Current Diabetes Reviews Pathobiology and Prevention of Cancer Chemotherapy-Induced Bone Growth Arrest, Bone Loss, and Osteonecrosis
Current Molecular Medicine Recent Approaches Targeting Beta-Amyloid for Therapeutic Intervention of Alzheimer's disease
Recent Patents on CNS Drug Discovery (Discontinued) Mapping the High Throughput SEREX Technology Screening for Novel Tumor Antigens
Combinatorial Chemistry & High Throughput Screening GPR55 and its Interaction with Membrane Lipids: Comparison with Other Endocannabinoid-Binding Receptors
Current Medicinal Chemistry Amyloidophilic Compounds for Prion Diseases
Infectious Disorders - Drug Targets Cervical Cancer Diagnosis: Insights into Biochemical Biomarkers and Imaging Techniques
Combinatorial Chemistry & High Throughput Screening An Update on Extemporaneous Preparation of Radiopharmaceuticals Using Freeze-Dried Cold Kits
Mini-Reviews in Medicinal Chemistry Role of the Renin-Angiotensin-Aldosterone System in the Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Advances in Interleukin-12 Gene Therapy for Acquired Liver Diseases
Current Gene Therapy siRNA Delivery by Stimuli-Sensitive Nanocarriers
Current Pharmaceutical Design The Role of Nitric Oxide Synthase Inhibitors in Schizophrenia
Current Medicinal Chemistry Intra-arterial Instillation of a Nociceptive Agent Modulates Cardiorespiratory Parameters Involving 5-HT3 and TRPV1 Receptors in Anesthetized Rats
Cardiovascular & Hematological Disorders-Drug Targets Glycoconjugates As Vaccines for Cancer Immunotherapy: Clinical Trials and Future Directions
Anti-Cancer Agents in Medicinal Chemistry Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD
Current Alzheimer Research Ion Channels on Microglia: Therapeutic Targets for Neuroprotection
CNS & Neurological Disorders - Drug Targets Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors as Anti-Angiogenic Agents in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery From QTL to Candidate Gene: A Genetic Approach to Alcoholism Research
Current Drug Abuse Reviews Angiotensin II, Cell Proliferation and Angiogenesis Regulator: Biologic and Therapeutic Implications in Cancer
Current Vascular Pharmacology Direct Evidence on the Immune-Mediated Spontaneous Regression of Human Cancer: An Incentive for Pharmaceutical Companies to Develop a Novel Anti-Cancer Vaccine
Current Pharmaceutical Design